These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

288 related items for PubMed ID: 12517276

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Once-per-cycle pegfilgrastim (Neulasta) for the management of chemotherapy-induced neutropenia.
    Crawford J.
    Semin Oncol; 2003 Aug; 30(4 Suppl 13):24-30. PubMed ID: 14508717
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Pegfilgrastim.
    Curran MP, Goa KL.
    Drugs; 2002 Aug; 62(8):1207-13; discussion 1214-5. PubMed ID: 12010086
    [Abstract] [Full Text] [Related]

  • 8. Pegfilgrastim: a granulocyte colony-stimulating factor with sustained duration of action.
    Lyman GH.
    Expert Opin Biol Ther; 2005 Dec; 5(12):1635-46. PubMed ID: 16318427
    [Abstract] [Full Text] [Related]

  • 9. Spotlight on pegfilgrastim in chemotherapy-induced neutropenia.
    Frampton JE, Keating GM.
    BioDrugs; 2005 Dec; 19(6):405-7. PubMed ID: 16392893
    [Abstract] [Full Text] [Related]

  • 10. Pegfilgrastim administered once per cycle reduces incidence of chemotherapy-induced neutropenia.
    Crawford J.
    Drugs; 2002 Dec; 62 Suppl 1():89-98. PubMed ID: 12479597
    [Abstract] [Full Text] [Related]

  • 11. An analysis of current neutropenia therapies, including pegfilgrastim.
    Gabrilove JL.
    Clin Cornerstone; 2006 Dec; 8 Suppl 5():S19-28. PubMed ID: 17379160
    [Abstract] [Full Text] [Related]

  • 12. Pharmacokinetics and pharmacodynamics of pegfilgrastim.
    Yang BB, Kido A.
    Clin Pharmacokinet; 2011 May; 50(5):295-306. PubMed ID: 21456630
    [Abstract] [Full Text] [Related]

  • 13. Safety and efficacy of pegfilgrastim compared to granulocyte colony stimulating factor (G-CSF) supporting a dose-intensive, rapidly cycling anti-metabolite containing chemotherapy regimen (Hyper-CVAD) for lymphoid malignancy.
    Lane SW, Crawford J, Kenealy M, Cull G, Seymour JF, Prince HM, Marlton P, Gill D, Mollee PN.
    Leuk Lymphoma; 2006 Sep; 47(9):1813-7. PubMed ID: 17064993
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Once-per-cycle pegfilgrastim versus daily filgrastim in pediatric patients with Ewing sarcoma.
    Wendelin G, Lackner H, Schwinger W, Sovinz P, Urban C.
    J Pediatr Hematol Oncol; 2005 Aug; 27(8):449-51. PubMed ID: 16096530
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Pegfilgrastim: current and future perspectives in the treatment of chemotherapy-induced neutropenia.
    Ricotta R, Cerea G, Schiavetto I, Maugeri MR, Pedrazzoli P, Siena S.
    Future Oncol; 2006 Dec; 2(6):667-76. PubMed ID: 17155894
    [Abstract] [Full Text] [Related]

  • 18. Maximizing the outcomes in cancer patients receiving chemotherapy through optimal use of colony-stimulating factor.
    Mucenski JW, Shogan JE.
    J Manag Care Pharm; 2003 Dec; 9(2 Suppl):10-4. PubMed ID: 14613339
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy.
    Green MD, Koelbl H, Baselga J, Galid A, Guillem V, Gascon P, Siena S, Lalisang RI, Samonigg H, Clemens MR, Zani V, Liang BC, Renwick J, Piccart MJ, International Pegfilgrastim 749 Study Group.
    Ann Oncol; 2003 Jan; 14(1):29-35. PubMed ID: 12488289
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.